GlassScriptPhysician profile
Moiz Khan
NPI 1215166780
$1,521.26
in general payments reported to CMS, 2019-2025
19 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.24 · 2022: $45.39 · 2023: $589 · 2024: $355 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $251.80 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $249.42 | 2023-2025 | Kimyrsa, Orbactiv, Vabomere |
| Pfizer INC. | $171.21 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $153.59 | 2020-2024 | Xarelto |
| Shionogi INC | $133.63 | 2023-2025 | Fetroja |
| Gilead Sciences, INC. | $108.30 | 2023-2025 | |
| La Jolla Pharmaceutical Company | $92.52 | 2023-2025 | Xerava, Xacduro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.92 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $46.04 | 2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.02 | 2023-2024 | Lifevest |
| Genzyme Corporation | $36.17 | 2025 | |
| Abbvie INC. | $33.73 | 2022-2023 | |
| Insmed, INC. | $30.22 | 2025 | Arikayce |
| Fisher Scientific Company L.L.C. | $27.35 | 2024 | Procalcitonin |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.93 | 2023 | Andexxa |
| Amgen INC. | $14.98 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.97 | 2023 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moiz Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.